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ABSTRACT
The pathological consequences of exposure to the
vaccine strain Brucella abortus S19 were evaluated
in 30 employees from vaccine-manufacturing
plants. Active brucellosis was diagnosed in 21
subjects, of whom only five recalled an accidental
exposure. Clinical manifestations were mild, and
only one patient presented a complication. After
antimicrobial therapy, initially symptomatic
patients either experienced clinical remission or
had mild persistent symptoms. This is the first
study reporting infection by B. abortus S19 among
workers from vaccine-manufacturing plants,
which in many cases was acquired from unnoticed
exposures. Measures to improve the safety of
B. abortus S19 handling should be implemented.
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Brucellosis, a zoonotic disease caused by different
species of Brucella, affects several regions, includ-
ing South America. Humans usually become
infected by contact with tissues or secretions from
cattle (Brucella abortus), goats and sheep (B. melit-
ensis), pigs (B. suis) and dogs (B. canis). Clinical
manifestations of human brucellosis range from
asymptomatic to acute disease, complicated
chronic disease or, occasionally, death.
The attenuated strain B. abortus S19 has been
the vaccine most widely used to prevent bovine
brucellosis. In some regions, this vaccine has been
replaced by the RB51 strain, a rough mutant that
is less virulent for cattle and does not interfere
with serological screening [1]. In spite of their
reduced virulence, both vaccines can be patho-
genic for humans, as has also been observed for
B. melitensis Rev-1 [2]. Infection due to these
vaccines is usually acquired from conjunctival
splashes, skin cuts or, occasionally, infectious
aerosols, and generally occurs in individuals
involved in animal vaccination [3–6]. An outbreak
of brucellosis among employees of a laboratory
manufacturing the Rev-1 vaccine has also been
reported [7]. In contrast, there are no reports of
human brucellosis due to S19 or RB51 strains
acquired within vaccine production plants.
The goal of this study was to analyze the clinical,
epidemiological and diagnostic aspects of workers
with potential exposure to B. abortus S19 in labora-
tories producing the S19 vaccine in Argentina.
Thirty employees from S19-manufacturing
plants (age 19–62 years, mean ± SD 33.5 ± 13.19
years, 20 males) were studied. They were referred
between February 1999 and June 2006 because they
had suggestive symptoms and ⁄ or serology posi-
tive for brucellosis. The clinical records of these
individuals were retrospectively analyzed. Indi-
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viduals were questioned about the nature of their
job, especially regarding actual or potential contact
with the S19 strain. An accidental exposure was
defined as an inhaled spray, a splash into the eyes
or broken skin, or a skin cut while handling the S19
vaccine [3]. Subjects were also questioned about
potential exposure to field strains of Brucella
(ingestion of unpasteurized milk or cheese, contact
with infected animals, etc.).
Serological tests for Brucella, including standard
tube agglutination (STA), 2-mercaptoethanol
(2ME), Rose Bengal (RB), and complement fixation
(CF) [8], were performed. Serologically suspected
active brucellosis was diagnosed in individuals
who fulfilled at least two of the following criteria:
STA titers ‡100, a positive RB result, a positive 2ME
result, or a positive CF result. When possible,
blood samples were obtained and sent to a refer-
ence centre for bacteriological studies.
Age, sex, and type and duration of clinical
symptoms upon admission were recorded.
A thorough physical examination was performed
in every case, and routine laboratory tests were
ordered. Imaging studies were performed in
patients with suspected osteoarticular or visceral
involvement. As B. abortus S19 infection may be
mild or asymptomatic [9], patients with serolog-
ically suspected active brucellosis were consid-
ered to have active infection, even in the absence
of clinical features.
Accidental exposure was reported by nine
(30%) laboratory employees. Exposures recalled
were percutaneous in six cases, inhalatory in three
and conjunctival in one (more than one route in
one case). Although four employees reported
previous occasional contact with Brucella field
strains without clinical manifestations, all these
episodes had occurred between 6 and 20 years
before and were considered to be unrelated to the
current clinical manifestations.
Blood cultures were performed for nine of the
30 patients and were negative in all cases. Sero-
logical studies were performed for all the 30
individuals. Positive results were obtained by RB
in 24 cases, by STA in 30 (16 with titers ‡100), by
2ME in 19, and by CF in 22. Overall, 21 employees
had serologically defined active brucellosis.
Current clinical manifestations were present in
15 of 21 laboratory employees with serologically
defined active infection (Table 1). Fever, asthenia,
arthralgia, headache and myalgia were the most
frequent clinical findings.
Antimicrobial therapy was prescribed to 11 of
21 patients with active brucellosis. Doxycycline
plus gentamicin was prescribed in seven cases
and doxycycline plus rifampin in three. A
pregnant woman was treated with amoxycillin
as recommended by Hall [10]. At the end of
therapy, six patients were asymptomatic and five
had few persistent symptoms (myalgia, arthral-
gia, headache, sweats). Ten infected patients were
not treated, either because they had spontaneous
remission, had mild symptoms only, or were lost
to follow-up.
Although B. abortus S19 infection has been
reported in personnel involved in handling
vaccines, the present study is, to our best knowl-
edge, the first to describe such infection among
workers from S19-manufacturing plants.
Although brucellosis is considered to be the
commonest laboratory-acquired infection world-
wide [11], most cases occur in clinical bacteriology
laboratories and are caused by field strains of
Brucella spp.[12–14].
Whereas personnel involved in handling vacines
usually acquire S19 infection via accidental inocu-
lation, facial splashes or skin exposure [15], most of
the laboratory employees studied here seemed to
be infected via unnoticed exposures (c. two-thirds
of the employees without accidental exposures had
active brucellosis). This finding agrees with
previous studies in personnel from diagnostic
bacteriology laboratories [16]. In addition, this
finding suggests that biosafety measures must be
improved in S19-manufacturing plants.
As this study was based on patients referred for
diagnosis, and not on an epidemiological inves-
tigation, we cannot rule out the possibility that
other workers from the vaccine-manufacturing
Table 1. Current clinical manifestations in 15 patients
with active brucellosis
Clinical manifestation No. of patients Frequencya (%)
Fever 8 53
Asthenia 7 47
Headache 6 40
Myalgia 6 40
Arthralgia 5 33
Sweats 4 27
Depression 3 20
Irritability 3 20
Insomnia 3 20
Weight loss 3 20
Digestive complaints 2 13
Sexual dysfunction 1 6.5
Adenopathies 1 6.5
Hepatic involvement 1 6.5
Lymphocytosis 1 6.5
aRelative to the total number of patients with current clinical manifestations.
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plants not included in this report may have been
infected also.
In the present study, blood cultures were
negative in all cases, which may relate to the
scarce number of tests performed and the low rate
of bacteriemia usually observed in human S19
infections. However, epidemiological data
strongly indicated that the only probable source
of Brucella infection was an occupational exposure
to the S19 vaccine.
In agreement with Young [9], this study dem-
onstrates that B. abortus S19 infection can produce
overt clinical disease. More than 50% of symp-
tomatic patients had a febrile illness, sometimes
accompanied by other characteristic pathological
findings. Most symptomatic patients experi-
enced clinical remission after initial antimicrobial
therapy.
This study shows for the first time that
employees from laboratories producing the S19
vaccine are at risk of exposure and may become
infected by this strain. To reduce the incidence of
such infection, safety measures should be
improved and training programmes reinforced.
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